Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer

References

• Allen TM, Sapra P, Moase E. (2002). Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7:889–94.
   PubMed Web of Science ®Google Scholar
• Apte A, Koren E, Koshkaryev A, Torchilin VP. (2014). Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biol Ther 15:69–80.
   PubMed Web of Science ®Google Scholar
• Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. (2013). Nanotechnology in cancer therapy. J Drug Target 21:904–13.
   PubMed Web of Science ®Google Scholar
• Bajelan E, Haeri A, Vali AM, et al. (2012). Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci 15:568–82.
   PubMed Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Perche F, et al. (2013). Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 335:191–200.
   PubMed Web of Science ®Google Scholar
• Biswas S, Dodwadkar NS, Deshpande PP, et al. (2013). Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur J Pharmaceut Biopharmaceut 84:517–25.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zak O, Aisen P, et al. (2004). Structure of the human transferrin receptor-transferrin complex. Cell 116:565–76.
   PubMed Web of Science ®Google Scholar
• Choi CH, Alabi CA, Webster P, Davis ME. (2010). Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 107:1235–40.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291–317.
   PubMed Web of Science ®Google Scholar
• Duggan S, Keating G. (2011). Pegylated liposomal doxorubicin. Drugs 71:2531–58.
   PubMed Web of Science ®Google Scholar
• El-Sayed A, Futaki S, Harashima H. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11:13–22.
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189–93.
   PubMed Web of Science ®Google Scholar
• Futaki S, Hirose H, Nakase I. (2013). Arginine-rich peptides: methods of translocation through biological membranes. Curr Pharm Des 19:2863–8.
   PubMed Web of Science ®Google Scholar
• Futaki S, Nakase I, Tadokoro A, et al. (2007). Arginine-rich peptides and their internalization mechanisms. Biochm Soc Trans 35:784–7.
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, et al. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836–40.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419–36.
   PubMed Web of Science ®Google Scholar
• Gao ZG, Lee DH, Kim DI, Bae YH. (2005). Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target 13:391–7.
   PubMed Web of Science ®Google Scholar
• Gatter KC, Brown G, Trowbridge IS, et al. (1983). Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 36:539–45.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. (2005). Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57:637–51.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144:646–74.
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, Barenholz Y. (1993). Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica Biophys Acta – Biomembranes 1151:201–15.
   PubMed Web of Science ®Google Scholar
• Hogemann-Savellano D, Bos E, Blondet C, et al. (2003). The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5:495–506.
   PubMed Web of Science ®Google Scholar
• Jain AS, Goel PN, Shah SM, et al. (2014). Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation. Biomed Pharmacother 68:429–38.
   PubMed Web of Science ®Google Scholar
• Jain RK. (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.”. J Clin Oncol 31:2205–18.
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, et al. (2001). Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870–7.
   PubMed Web of Science ®Google Scholar
• Kakudo T, Chaki S, Futaki S, et al. (2004). Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43:5618–28.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Hayashi Y, Mizuno R, Harashima H. (2011). Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. J Control Release 156:374–80.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Kogure K, Futaki S, Harashima H. (2006). High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 281:3544–51.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Ishida T, Okada Y, et al. (2007). Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 329:94–102.
   PubMed Web of Science ®Google Scholar
• Kolhatkar R, Lote A, Khambati H. (2011). Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. Curr Drug Discov Technol 8:197–206.
   PubMedGoogle Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. (2012). Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther 13:50–60.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. (2013). Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett 334:293–301.
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. (2016). Nanocarriers for cancer-targeted drug delivery. J Drug Target 24:179–91.
   PubMed Web of Science ®Google Scholar
• Li X, Ding L, Xu Y, et al. (2009). Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 373:116–23.
   PubMed Web of Science ®Google Scholar
• Lin J, Shigdar S, Fang DZ, et al. (2014). Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model. PLoS One 9:e103736.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu X-N, Wang G-L, et al. (2017). A dual-mediated liposomal drug delivery system targeting the brain: rational construction, integrity evaluation across the blood–brain barrier, and the transporting mechanism to glioma cells. Int J Nanomed 12:2407–25.
   PubMed Web of Science ®Google Scholar
• Magadala P, Vlerken L, Shahiwala A, Amiji M. (2008). Multifunctional polymeric nanosystems for tumor-targeted delivery. In: Torchilin V, ed. Multifunctional pharmaceutical nanocarriers. Vol. 4, New York: Springer, 33–66.
   Google Scholar
• Mayer LD, Reamer J, Bally MB. (1999). Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharmaceut Sci 88:96–102.
   PubMed Web of Science ®Google Scholar
• Mehra NK, Mishra V, Jain NK. (2013). Receptor-based targeting of therapeutics. Ther Deliv 4:369–94.
   PubMedGoogle Scholar
• Minotti G, Menna P, Salvatorelli E, et al. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229.
   PubMed Web of Science ®Google Scholar
• Nie Y, Ji L, Ding H, et al. (2012). Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics 2:1092–103.
   PubMed Web of Science ®Google Scholar
• Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. (2015). Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces 136:514–26.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–9.
   PubMed Web of Science ®Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. (2012). Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–25.
   PubMed Web of Science ®Google Scholar
• Ohe Y, Ohashi Y, Kubota K, et al. (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–23.
   PubMed Web of Science ®Google Scholar
• Peng X, Chen B, Lim CC, Sawyer DB. (2005). The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 5:163–71.
   PubMed Web of Science ®Google Scholar
• Qin LI, Wang C-Z, Fan H-J, et al. (2014). A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy. Oncol Lett 8:2000–6.
   PubMed Web of Science ®Google Scholar
• Sawant R, Torchilin V. (2010). Intracellular transduction using cell-penetrating peptides. Mol Biosyst 6:628–40.
   PubMed Web of Science ®Google Scholar
• Sawant RR, Jhaveri AM, Koshkaryev A, et al. (2013). The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy. J Drug Target 21:630–8.
   PubMed Web of Science ®Google Scholar
• Schmidt N, Mishra A, Lai GH, Wong GC. (2010). Arginine-rich cell-penetrating peptides. FEBS Lett 584:1806–13.
   PubMed Web of Science ®Google Scholar
• Sriraman SK, Salzano G, Sarisozen C, Torchilin V. (2016). Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. Eur J Pharm Biopharm 105:40–9.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2006). Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532–55.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2006). Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8:343–75.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2008). Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90:604–10.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197:3–53.
   PubMedGoogle Scholar
• Torchilin VP, Levchenko TS, Lukyanov AN, et al. (2001). p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta (BBA) – Biomembranes 1511:397–411.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Rammohan R, et al. (2003). Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A 100:1972–7.
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Omelyanenko VG, Papisov MI, et al. (1994). Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1195:11–20.
   PubMed Web of Science ®Google Scholar
• Tortorella S, Karagiannis TC. (2014). The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems. Curr Drug Deliv 11:427–43.
   PubMed Web of Science ®Google Scholar
• Vives E, Brodin P, Lebleu B. (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010–7.
   PubMed Web of Science ®Google Scholar
• Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR. (2016). Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur J Pharm Sci 86:125–35.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Alakhova DY, Kim JO, et al. (2013). A simple way to enhance Doxil(R) therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release 168:61–9.
   PubMed Web of Science ®Google Scholar